Kopran Limited · NSE:KOPRAN
Kopran — H1 FY2025-26 Earnings Presentation
22 slides from Kopran's earnings presentation, Nov 12, 2025
Slide 1: Cover letter to stock exchanges
November 12, 2025 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear S
Slide 2: Corporate Presentation HY - FY 2025-26
CORPORATE PRESENTATION HY - FY 2025-26
Slide 3: This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-2 Q-1 Q-2 HY PARTICULARS 2025-26 2025-26 2024-25 2025-26 Revenue from Operations 11,791 13,522 15,156 25,313 EBITDA* 296 1,413 1,474 1,709 Finance Costs 209 254 223 463 Forex Gain/Loss -824 289 85 -585 Depreciation 428 426 385 854 Tax Expenses -170 244 226 74 Net Profit -992 745 738 -247 EBITDA Ma
Slide 6: Operational Performance
OPERATIONAL PERFORMANCE
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX Q2 - FY 2025-26 (Rs. in Lakhs) HY 2025-26 (Rs. in Lakhs) 229 31 178 26 505 129 508 34 774 Anti- Diabetic 1323 Anti- Diabetic 1,459 Anti- Infective Antibiotic-Urological 2088 38 Anti-Hypertensive 38 Antibiotic-Urological 2574 652 Anti-Thrombotic An
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX Q2 - FY 2025-26 (Rs. in Lakhs) HY 2025-26 (Rs. in Lakhs) 6056 2512 Export Sales Export Sales Local Sales Local Sales 9814 5055 Total Rs. 8,303 Lakhs Total Rs. 15,870 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP Q2 - FY 2025-26 (Rs. in Lakhs) HY 2025-26 (Rs. in Lakhs) -64 152 429 956 4165 Africa Africa CANADA Canada 1746 Latem Latem Middle East and North Middle East and North Africa Africa South Africa South Africa Southeast Asia Southeast Asia
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX Q2 - FY 2025-26 (Rs. in Lakhs) HY 2025-26 (Rs. in Lakhs) 1384 3804 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 2633 5291 Total Rs. 4,017 Lakhs Total Rs. 9,095 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins - Non-Sterile & Sterile ❖ Urological ❖ One of the leaders in Atenolol
Slide 14: Formulations Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL ❖ Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Financial Performance
FINANCIAL <—, PERFORMANCE Kopran
Slide 18: Snapshot
SNAPSHOT EBITDA * (Rs. in LAKHS) SALES/OTHER INCOME (Rs. in LAKHS) 8,739 8,178 62,920 63,359 7,441 7,290 55,405 50,980 48,813 5,180 36,013 4,696 25,331 1,709 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 HY-25-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 HY-25-26 FINANCE COSTS (Rs. in LAKHS)
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( Rs. in Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 8,178 22.4 7,441 7,290 20.1 14.5 5,180 11.8 11.5 9.4 4,696 8.4 11 6.3 7.6 1,709 1.4 -0.5 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 HY-25-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 HY-25-
Slide 20: Financial summary (Rs. in Lakhs)
(Rs. in Lakhs) PARTICULARS HY FY FY FY FY FY FY FY 2025-26 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 Equity Share Capital 4,829 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 45,280 47,006 44,303 39,104 37,796 20,178 14,643 Net Worth 50,108 51,835 49,125 43,925 42,617 24,503 18,968 Fixed Ass
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MR. VARUN SURENDRA SOMANI EXECUTIVE VICE CHAIRMAN DIRECTOR DIRECTOR MR. CHANDRESH GANDHI MRS. MAMTA BIYANI MR. NARAYAN ATAL INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P